RNAZ Projected Dividend Yield
TransCode Therapeutics Inc ( NASDAQ : RNAZ )TransCode Therapeutics is a biopharmaceutical company focused primarily on developing and commercializing drugs and diagnostics for treating and identifying metastatic disease. Co.'s primary therapeutic candidate, TTX-MC138, targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Co.'s other preclinical programs include two solid tumor programs: TTX-siPDL1, a small interfering RNA (siRNA)-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. 20 YEAR PERFORMANCE RESULTS |
RNAZ Dividend History Detail RNAZ Dividend News RNAZ Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |